House dust mite sublingual immunotherapy: a double‐blind, placebo‐controlled study in elderly patients with allergic rhinitis

Bożek, Andrzej; Ignasiak, Beata; Filipowska, Barbara; Jarząb, Jerzy

doi:10.1111/cea.12039

Cited by 88 publications

(66 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…19 In another field trial of HDM sublingual drops in 108 elderly subjects, onset of action was not formally assessed, but clinical effect on nasal symptoms appeared to begin at approximately 6 months. 20 Thus, the onset of action of 12 DU of MK-8237 appears to be almost twice as fast as has been reported for HDM SLIT in other trials.…”

Section: Discussionmentioning

confidence: 55%

Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber

Nolte

Maloney

Nelson

et al. 2015

Journal of Allergy and Clinical Immunology

139

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 55%

Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber

Nolte

Maloney

Nelson

et al. 2015

Journal of Allergy and Clinical Immunology

139

View full text Add to dashboard Cite

“…However, there are several contraindications for AIT including comorbidities, such as autoimmune diseases and malignancies, concomitant drug treatments, particularly β-blockers and angiotensin-converting enzyme inhibitors (ACEI), pregnancy for induction therapy, and, currently, severe asthma [60,61]. There are also some concerns about the age limits for AIT use, although elderly people have shown good tolerance and clinical improvements with SLIT for mite allergy [62,63]. These concerns also affect to very young children but this topic will be discussed in a section below (see AIT efficacy in pediatric populations).…”

Section: Indications and Contraindications Of Ait In Asthmamentioning

confidence: 99%

Specific allergen immunotherapy for the treatment of allergic asthma: a review of current evidence

Domínguez‐Ortega

Delgado

Blanco

et al. 2017

J Investig Allergol Clin Immunol

View full text Add to dashboard Cite

Asthma is frequently associated with atopy, characterized by the production of specific immunoglobulin E in response to environmental allergens. Currently, two types of allergen immunotherapy (AIT) are used in clinical practice: subcutaneous and sublingual immunotherapy, both accepted as key components of the therapeutic repertoire for allergic rhinitis and conjunctivitis. However, their role in asthma remains controversial. The present document is aimed at providing the clinicians with a review of the evidence on the use of AIT in asthma, focusing on the most relevant aspects of its mechanism of action, its efficacy, and existing data on safety, tolerability, and cost-effectivity, both in pediatric and adult populations. A systematic search of MEDLINE, Cochrane, and Clinical Trials databases from 2000 to April of 2016 was carried out by a panel of experts from the Spanish Allergy and Clinical Immunology Scientific Society. Relevant studies prior to the year 2000 included in ulterior systematic reviews were also considered. More than 4000 articles were identified during the search and 241 were selected to retrieve available evidence on AIT, which was graded according to the Oxford classification. All the group members reviewed the resulting text until the final version reached the consensual agreement. A summary of recommendations on the more relevant topics are proposed. The role of AIT as a valuable therapeutic strategy for prevention of exacerbation and progressive decline in lung function is highlighted. Future research should include specific tools for asthma evaluation when assessing AIT effectiveness in asthmatic patients. ResumenEl asma se asocia frecuentemente con alergia, entendida ésta como la producción de IgE específica frente a alérgenos ambientales. Actualmente, existen dos tipos de inmunoterapia específica con alérgenos (ITE) para la práctica clínica habitual: subcutánea y sublingual, ambas indicadas en el tratamiento de la rinitis y la conjuntivitis alérgicas. Sin embargo, su papel en el asma resulta todavía controvertido. Dominguez-Ortega J, et al.

show abstract

“…AIT is seldom offered to older patients due to safety concerns and the perception that the allergic disease is already 'too advanced' and unlikely to benefit from AIT. A recent study has demonstrated significant clinical efficacy of HDM SLIT in subjects of age >60 years who had a long history of perennial HDM AR [74]. Another recent double-blind placebo-controlled study from the same group evaluating the clinical efficacy of grass pollen SLIT (78 allergic subjects aged 60-70 years) reported 64% decrease in nasal symptoms versus 7% with placebo [75].…”

Section: Role Of Allergen Immunotherapy In the Elderly Patientmentioning

confidence: 99%

Current developments for improving efficacy of allergy vaccines

Sandrini

Rolland

O’Hehir

2015

Expert Review of Vaccines

View full text Add to dashboard Cite

Allergic diseases are prevalent worldwide. Allergen immunotherapy (AIT) is a current treatment for allergy, leading to modification of the natural course of disease. Mechanisms of efficacy include Treg through release of IL-10 and TGF-β and specific IgG4 blocking antibodies. Subcutaneous and sublingual routes are popular, but uptake is limited by inconvenience and safety concerns. Inclusion criteria limit application to a small proportion of allergic patients. New forms of immunotherapy are being investigated for more efficacious, convenient and safer options with promising advances in recent years. The rationale of reducing vaccine allergenicity to increase safety while improving immunogenicity led to investigation of T-cell epitope-based peptides and recombinant allergen derivatives. Additionally, different routes of administration and adjuvants and adjunct therapies are being explored. This review discusses the current status of AIT and recent advances to improve clinical efficacy, safety and long-term immune tolerance.

show abstract

House dust mite sublingual immunotherapy: a double‐blind, placebo‐controlled study in elderly patients with allergic rhinitis

Abstract: Sublingual allergen-specific immunotherapy in elderly patients with a HDM allergy to D. pteronyssinus and D. farinae generated a significant clinical improvement in the active group compared with the placebo group, particularly during the heating season. This therapy was well tolerated.

Cited by 88 publications

References 21 publications

Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber

Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber

Specific allergen immunotherapy for the treatment of allergic asthma: a review of current evidence

Current developments for improving efficacy of allergy vaccines

Contact Info

Product

Resources

About